文献速递MDS 与骨髓增殖性肿瘤

ADORE:芦可替尼联合其他新型疗法治疗骨髓纤维化患者的开放平台研究

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis.
PubMed 文献 · Blood Adv · 2025-01-01

ADORE 是一项 1b/2 期开放平台研究,评估新型药物联合芦可替尼在芦可替尼单药反应欠佳的骨髓纤维化患者中的安全性、疗效和药代动力学。第一部分共纳入 44 例患者,多数接受芦可替尼联合 siremadlin(N=23),该联合方案在 24 周时观察到最显著的脾体积缩小,siremadlin 30 mg 被选为推荐 2 期剂量。

要点

  • ADORE 为 1b/2 期开放平台研究,纳入芦可替尼单药反应欠佳的骨髓纤维化患者 44 例。
  • 多数患者接受芦可替尼联合 siremadlin(N=23),常见不良事件为胃肠道和血液学毒性。
  • siremadlin 30 mg 每日一次口服(28 天周期第 1–5 天)被选为推荐 2 期剂量。

核心结论

  • ADORE 现有数据提示,在芦可替尼单药反应欠佳的患者中,新型药物联合芦可替尼具有可行性和获益。

研究设计与样本

  • ADORE 是一项 1b/2 期研究,采用创新的开放平台设计,评估新型化合物联合芦可替尼在骨髓纤维化患者中的安全性、疗效和药代动力学。
  • 研究第一部分共纳入 44 例对芦可替尼单药反应欠佳的患者,接受芦可替尼联合 siremadlin、rineterkib、sabatolimab、crizanlizumab 或 NIS793。
  • 多数患者被分配接受芦可替尼联合 siremadlin(N=23)。

主要发现

  • siremadlin 相关最常见不良事件为胃肠道反应(恶心和腹泻)和血液学毒性(血小板减少、贫血和中性粒细胞减少)。
  • 24 周时最显著的脾体积缩小(SVR)见于芦可替尼联合 siremadlin 30 mg 组。
  • 第 24 周观察到 JAK2V617F 等位基因负荷百分比下降,尤其在若干达到 SVR 的患者中。
  • 接受 siremadlin 的患者生长分化因子 15 蛋白水平升高,表明下游 p53 靶点受到在靶调节。

关键数值与推荐

  • siremadlin 30 mg 每日一次口服,28 天周期第 1–5 天给药,被选为推荐 2 期剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, ∼70% of patients discontinue ruxolitinib after ∼5 years, a third of whom report suboptimal splenic response. ADORE was a phase 1b/2 study with an innovative open platform design that assessed the safety, efficacy, and pharmacokinetics of novel compounds in combination with ruxolitinib in patients with MF who had a suboptimal response to ruxolitinib alone. A total of 44 patients were enrolled in part 1 of the study of ruxolitinib in combination with siremadlin, rineterkib, sabatolimab, crizanlizumab, or NIS793. Most patients were allocated to receive ruxolitinib plus siremadlin (N = 23). The most frequent adverse events with siremadlin were gastrointestinal (nausea and diarrhea) and hematological (thrombocytopenia, anemia, and neutropenia). Siremadlin 30 mg orally once daily on days 1 to 5 of a 28-day cycle was selected as the recommended phase 2 dose. The most robust spleen volume reduction (SVR) at 24 weeks was observed with ruxolitinib plus siremadlin 30 mg. Reductions in percent JAK2V617F allele burden at week 24 were observed, notably in several patients with SVR. An increase in growth differentiation factor 15 protein levels in patients receiving siremadlin demonstrated the on-target modulation of downstream p53 targets. Overall, available data from ADORE suggest the feasibility and benefits of combining novel agents with ruxolitinib in patients with suboptimal response to ruxolitinib alone. This trial was registered at www.clinicaltrials.gov as #NCT04097821.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ross DM, Heidel FH, Perkins AC, et al. ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis. Blood Adv. 2025. PMID: 40334082. doi:10.1182/bloodadvances.2025015860

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。